Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improve...

Full description

Bibliographic Details
Main Authors:	Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	EClinicalMedicine
Subjects:	Her-2 positive breast cancer Bevacizumab Neoadjuvant Positron emission tomography Early pet assessment Δsuvmax
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537020303102

Similar Items

Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer
by: Takahiro Einama, et al.
Published: (2022-07-01)

Clinical Significance of Incidental 18-FDG Uptake in Nasopharynx on PET/CT Scanning
by: İmdat Yüce, et al.
Published: (2019-11-01)

Relationship Between SUVmax and Ki-67 Expression in Breast Cancer
by: Meriç Emre Bostancı, et al.
Published: (2020-09-01)

The Role of Preoperative 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Retroperitoneal Sarcoma
by: Sung Jun Jo, et al.
Published: (2022-05-01)

Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy
by: Wenbin Yan, et al.
Published: (2023-02-01)

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma
by: Sanjeet Kumar Jaiswal, et al.
Published: (2020-09-01)

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients
by: Amin Haghighat Jahromi, et al.
Published: (2020-12-01)

Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
by: Linping Ke, et al.
Published: (2021-05-01)

SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma
by: Yushi Nagaki, et al.
Published: (2021-04-01)

Maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients
by: Xue-Song Sun, et al.
Published: (2019-09-01)

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma
by: Carolin Prexler, et al.
Published: (2022-12-01)

Utilidade do PET/CT na caracterização do nódulo solitário pulmonar
by: Ana Graça, et al.
Published: (2011-05-01)

Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
by: Xiaoqing Dong, et al.
Published: (2024-12-01)

Prediction of 2-[<sup>18</sup>F]FDG PET-CT SUVmax for Adrenal Mass Characterization: A CT Radiomics Feasibility Study
by: Arnaldo Stanzione, et al.
Published: (2023-06-01)

Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway
by: Aditya Prakash Sharma, et al.
Published: (2023-11-01)

Diagnosis value of 18F-Fluoro-d-glucose positron emission tomography-computed tomography in pulmonary hamartoma: a retrospective study and systematic review
by: Sheng Ye, et al.
Published: (2023-02-01)

Pretreatment SUVmax value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
by: Gokhan Yaprak, et al.
Published: (2019-06-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials
by: Anne-Victoire Michaud-Robert, et al.
Published: (2020-09-01)

DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma
by: Xu-Sheng Liu, et al.
Published: (2023-08-01)

18F-Fluorodeoxyglucose Positron Emission Tomography Is Useful in the Evaluation of Prognosis in Retroperitoneal Sarcoma
by: Toru Wakamatsu, et al.
Published: (2021-09-01)

Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer
by: Tarik Sengoz, et al.
Published: (2023-04-01)

The correlation of tumor markers, neutrophil/lymphocyte ratio and FDG PET/CT measures in pancreatic cancer
by: Reyhan Koroglu, et al.
Published: (2021-07-01)

Factors Influencing Diagnostic Success of Computed Tomography-guided Transthoracic Needle Biopsy in Intrathoracic Lesions: An Experience of a Reference Chest Disease Hospital
by: Hülya Abalı, et al.
Published: (2023-02-01)

A case of primary small cell neuroendocrine carcinoma of the uterus
by: Taku Miyanaga, MD, et al.
Published: (2022-11-01)

Hounsfield unit value has null effect on thyroid nodules at 18F-FDG PET/CT scans
by: Filiz Eksi Haydardedeoglu, et al.

Role of PET/CT in post-therapeutic assessment of bronchogenic carcinoma
by: Amira Ayman Shaheen, et al.
Published: (2021-05-01)

Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with  Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma
by: Hongliang REN, et al.
Published: (2016-04-01)

Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer
by: Yoji YAMAGISHI, et al.
Published: (2019-11-01)

Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy
by: Kyu Hye Choi, et al.
Published: (2021-03-01)

Beyond lymph nodes: 18F-FDG PET/CT in detection of unusual sites of extranodal lymphoma
by: Amal Ibrahim Ahmed Othman, et al.
Published: (2019-09-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: In Hee Lee, et al.
Published: (2020-11-01)

Avaliação do SUVmax na captação do [68Ga]Ga-DOTA-TATE PET/CT em doentes com tumores neuroendócrinos: revisão de literatura
by: Carolina Maricato, et al.
Published: (2022-11-01)

The Value of Semiquantitative Parameters Derived from <sup>18</sup>F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer
by: Luca Urso, et al.
Published: (2022-11-01)

Multiple myeloma: characterization of patients through the analysis of semiquantitative parameters with 18F-FDG PET
by: Maria Silvia De Feo, et al.
Published: (2023-06-01)

Significance of metabolic parameters and biochemical indexes of 18F-FDG PET/CT in the mid-term evaluation and prognosis of diffuse large B-cell lymphoma
by: Zhang Fan, Zhang Guoxu, Liu Xiuting, Wang Jigang, Liu Yanqin, Tong Danjiang, Liu Jinghua, Zhou Fan
Published: (2022-03-01)

FDG-PET/CT tumor to liver SUV ratio (TLR), tumor SUVmax, and tumor size: can this help in differentiating squamous cell carcinoma from adenocarcinoma of the lung?
by: Amr Muhammad Abdo Salem, et al.
Published: (2022-05-01)

Hybrid imaging of vascular graft infection by positron emission tomography with computed tomography using fluorine-18-labeled fluorodeoxyglucose: The Serbian National PET Center experience
by: Šaponjski Jelena, et al.
Published: (2019-01-01)

The maximum standardized uptake value of <sup>18</sup> F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
by: Zhang Jian, et al.
Published: (2013-01-01)

18F-FDG positron emission tomography in the diagnosis and staging of marginal zone non-Hodgkin lymphomas
by: M. M. Khodzhibekova, et al.
Published: (2016-02-01)